RT Journal Article
SR Electronic
T1 Functional and quantitative evaluation of BNT162b2 SARS-CoV-2 vaccine-induced immunity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.26.21257884
DO 10.1101/2021.05.26.21257884
A1 Hitoshi Kawasuji
A1 Yoshitomo Morinaga
A1 Hideki Tani
A1 Yumiko Saga
A1 Makito Kaneda
A1 Yushi Murai
A1 Akitoshi Ueno
A1 Yuki Miyajima
A1 Yasutaka Fukui
A1 Kentaro Nagaoka
A1 Chikako Ono
A1 Yoshiharu Matsuura
A1 Hideki Niimi
A1 Yoshihiro Yamamoto
YR 2021
UL http://medrxiv.org/content/early/2021/05/30/2021.05.26.21257884.abstract
AB Objectives Vaccines against severe acute respiratory syndrome coronavirus-2 have been introduced. To investigate whether the vaccine provides protective immunity effectively, the amount and function of vaccine-induced antibodies were evaluated.Methods Sera from 13-17 days after the second dose of the Pfizer BNT162b2 vaccine were collected from healthcare workers at the University of Toyama (n=740). Antibody levels were quantitatively measured by the anti-receptor binding domain antibody test (anti-RBD test), and neutralising activity against pseudotyped viruses displaying wild-type (WT) and mutant spike proteins (B.1.1.7- and B.1.351-derived variants) were assayed using a high-throughput chemiluminescent reduction neutralising test (htCRNT). Basic clinical characteristics were obtained from questionnaires.Results Antibodies were confirmed in all participants in both the anti-RBD test (median 2112 U/mL, interquartile range [IQR] 1275–3390 U/mL) and the htCRNT against WT (median % inhibition >99.9, IQR >99.9 to >99.9). For randomly selected sera (n=61), 100.0% were positive for htCRNT against the B.1.1.7- and B.1.351-derived variants. Among those who answered the questionnaire (n=237), the values of the anti-RBD test were negatively correlated with age for females (p<0.01; r = -0.31, 95% confidence interval -0.45 to -0.16). Systemic symptoms after vaccination were related to higher values of the anti-RBD test (median 2425, IQR 1450 – 3933 vs. median 1347, IQR 818 – 2125 for no symptoms; p<0.01).Conclusions The BNT162b2 vaccine produced sufficient antibodies in terms of quality and quantity which could neutralise emerging variants. Antibody induction can be affected by age and sex but will still be at a sufficient level.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Research Program on Emerging and Re-emerging Infectious Diseases from AMED Grant No. JP20he0622035 (YM, HT, and YY) and the Research Funding Grant by the president of the University of Toyama (YM, NH, and YY).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was performed in accordance with the Declaration of Helsinki and was approved by the ethical review board of the University of Toyama (approval No.: R2019167)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll available data are in the manuscript.